Award
NIH Reporter #5R01CA288880-03
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer
Recipient
National Cancer Institute (NCI), part of NIH
Award Amount
$402,600.00
Ceiling
$402,600.00
Awarded
March 09, 2026
Identifier
5R01CA288880-03
NIH grant awarded for research on HER2-targeted therapy in locally advanced rectal cancer, focusing on clinical trials and innovative treatment methods.
Description
This NIH grant supports research on biomarker-directed therapy for HER2-amplified rectal cancer, involving clinical trials, correlative studies, and the use of patient-derived organoids. The project aims to evaluate the efficacy of HER2-targeted induction therapy and its potential to transform treatment approaches, including organ-sparing management.